Malignant brain tumor Malignant brain tumor, 18F-fluciclovine, recurrence, radiation necrosis
Conditions
Interventions
Post-treatment evaluation of malignant brain tumors using 18F-fluciclovine PET/CT
Q000000981
diagnostic imaging
Sponsors
Noguchi Kyo
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Meet all of the following criteria: (1) Diagnosed with malignant brain tumors (malignant glioma or metastatic brain tumor) histopathologically and have been undergoing radiation therapy, suspicion of recurrent tumor or radiion necrosis post-radiation therapy of malignant brain tumors (2) Ages 20 and over (3) We obtain written consent, keep to the rules for participating in the study, undergone the medical examinations and tests set out in the study implementation plan, and are judged by the principal investigator (subinvestigator) to be able to report any symptoms, etc.
Exclusion criteria
Exclusion criteria: Any of the following criteria: (1) Medical history of hypersensitivity to 18F-fluciclovine (2) Principal investigator (subinvestigator) judges to be inappropriate as subjects of this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 18F-fluciclovine uptake Degree uptake of 18F-fluciclovine | — |
Secondary
| Measure | Time frame |
|---|---|
| Consider pitfalls, including the detection of incidental lesions other than the primary evaluation lesions and accumulation in normal tissues. | — |
Contacts
Public ContactNorihito Naruto
Toyama University Hosipital
Outcome results
None listed